Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Executive Summary

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

You may also be interested in...



PBM Rebates Drive List-To-Net Price Gap For Insulins, Study Shows; More Fodder For Reforms?

Mandatory government discounts had a much smaller impact on net prices than voluntary rebates in commercial and Medicare Part D plans, researchers determine. The cap on Medicaid rebates, which will be eliminated in 2024, may have contributed to at least some of the disparity.

‘Why Stop At Insulin?’ Senate Democrats Want More List Price Moves From Pharma

Pharma was unable to punt all the drug pricing blame to pharmacy benefits managers at the 10 May Senate HELP hearing on affordable insulin, though the PBM-focused fury was more bipartisan.

Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders

Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel